BiomX Inc. (NYSEAMERICAN:PHGE) Sees Significant Increase in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) saw a large increase in short interest in May. As of May 15th, there was short interest totaling 197,532 shares, an increase of 116.4% from the April 30th total of 91,280 shares. Based on an average daily trading volume, of 295,133 shares, the short-interest ratio is currently 0.7 days. Currently, 15.8% of the shares of the stock are sold short.

Insider Buying and Selling

In other BiomX news, Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 21.80% of the company’s stock.

Get BiomX alerts:

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. acquired a new stake in BiomX Inc. (NYSEAMERICAN:PHGE – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors.

BiomX Trading Down 17.5%

BiomX stock traded down $0.22 during mid-day trading on Monday, hitting $1.04. The company’s stock had a trading volume of 1,016,679 shares, compared to its average volume of 17,600,592. The firm has a market capitalization of $10.56 million, a PE ratio of -0.32 and a beta of 1.17. BiomX has a 1 year low of $0.36 and a 1 year high of $14.71. The stock’s fifty day moving average is $1.99 and its two-hundred day moving average is $3.49.

BiomX (NYSEAMERICAN:PHGE – Get Free Report) last released its quarterly earnings results on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. On average, equities analysts expect that BiomX will post -5.85 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lowered BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $26.00.

Get Our Latest Stock Analysis on BiomX

BiomX Company Profile

(Get Free Report)

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.

Featured Stories

• Five stocks we like better than BiomX
• Why These Three Big Buybacks Are Sending Very Different Signals to Investors
• Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
• Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
• Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.